Anthony Turkiewicz is a Rheumatology/Immunology physician. OpenAlex indexes 18 publications with 4,908 citations (h-index 11).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
12 Office Park Cir
Mountain Brk, AL 352232521
Telephone
205-933-0320Provider last certified this registry record 29 Aug 2023.
Industry payments
37 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year202560 payments$79,202openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year202574 payments$60,143openpaymentsdata.cms.gov ↗
- UCB, Inc.Program year202579 payments$45,564openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
77.2%TNF inhibitor61%Golimumab87%Infliximab13%Enbrel Sureclick0%Humira(Cf) Pen0%Humira Pen0%Part D + Part B<11 patientsSelective T Cell Costimulation Modulator14.9%Abatacept100%Part B, office-administered≥15 patients+ 5 more classes in this area
Dermatology
13.8%Corticosteroid13.8%Methylprednisolone acetate99%Methylprednisolone1%Methylprednisolone sodium succinate1%Part D + Part B≥88 patientsMusculoskeletal
3.9%RANK Ligand Inhibitor2.5%Denosumab100%Part B, office-administered≥16 patientsMuscle Relaxant0.5%Cyclobenzaprine Hcl55%Methocarbamol45%Part D≥36 patients+ 6 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2007–2007 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”